GRK4 Polymorphisms Blood Pressure Response to Candesartan
- Registration Number
- NCT01629225
- Lead Sponsor
- Third Military Medical University
- Brief Summary
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.
- Detailed Description
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- men and women with mild to moderate essential hypertension in southwestern Han Chinese
Exclusion Criteria
- subjects unwilling to participate or subjects did not have all measurement required,
- subjects who were on medications, which affect blood pressure or
- whose DNA failed to amplify and 8 with errors in Mendelian segregation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description candesartan Candesartan All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
- Primary Outcome Measures
Name Time Method The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension two years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Cardiology, Daping Hospital, The Third Military Medical University
🇨🇳Chongqing, China